AURA

AURA

USD

Aura Biosciences Inc. Common Stock

$6.630-0.460 (-6.488%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$7.090

Máximo

$7.120

Mínimo

$6.615

Volume

0.28M

Fundamentos da empresa

Capitalização de mercado

411.1M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.30M

Bolsa de valores

NGM

Moeda

USD

Faixa de 52 semanas

Mínimo $4.345Atual $6.630Máximo $12.378

Notícias relacionadas

Analyst Upgrades

HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22

HC Wainwright & Co. analyst Andres Maldonado assumes Aura Biosciences with a Buy rating and announces Price Target of $22.

Ver mais
HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22
Analyst Upgrades

JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target

JMP Securities analyst Jonathan Wolleben reiterates Aura Biosciences with a Market Outperform and maintains $19 price target.

Ver mais
JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target
GlobeNewswire

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today

Ver mais
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewswire

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today

Ver mais
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of

Ver mais
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.